bms204352 has been researched along with naproxen in 3 studies
| Studies (bms204352) | Trials (bms204352) | Recent Studies (post-2010) (bms204352) | Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) |
|---|---|---|---|---|---|
| 49 | 1 | 12 | 4,551 | 1,057 | 1,429 |
| Protein | Taxonomy | bms204352 (IC50) | naproxen (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 1.1642 | |
| Hormone-sensitive lipase | Rattus norvegicus (Norway rat) | 1.2 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 4.0203 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3.8725 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.06 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 0.5867 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 1.26 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 3.36 | |
| Solute carrier family 22 member 6 | Homo sapiens (human) | 5.8 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 review(s) available for bms204352 and naproxen
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
2 other study(ies) available for bms204352 and naproxen
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |